Global Mycoplasma Testing Market

Mycoplasma Testing Market Size, Share, Growth Analysis, By Product (Instruments, Kits & Reagents), By Technology (PCR, ELISA), By Application (Cell Line Testing, Virus Testing), By End-User (Academic Research Institutes, Cell Banks), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35I2219 | Region: Global | Published Date: December, 2025
Pages: 219 |Tables: 66 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global Mycoplasma Testing Market size was valued at USD 897.33 Million in 2024 and is poised to grow from USD 967.32 Million in 2025 to USD 1764.09 Million by 2033, growing at a CAGR of 7.8% during the forecast period (2026–2033).

    Established and emerging companies compete with each other in the mycoplasma testing industry, introducing competition. Companies often depend on strategic alliances and innovative testing methods to firmly position themselves within the market. Regional companies are also becoming more aggressive as they expand their ranges to suit local customers. 'Thermo Fisher Scientific Inc. (USA)', 'Merck KGaA (Germany) ', 'Lonza Group Ltd. (Switzerland) ', 'Charles River Laboratories International Inc. (USA) ', 'Eurofins Scientific SE (Luxembourg) ', 'Roche Diagnostics (Switzerland) ', 'Agilent Technologies Inc. (USA) ', 'Bio-Rad Laboratories Inc. (USA) ', 'Sartorius AG (Germany) ', 'bioMerieux SA (France) ', 'Asahi Kasei Corporation (Japan) ', 'American Type Culture Collection (ATCC) (USA) ', 'Bionique Testing Laboratories Inc. (USA) ', 'InvivoGen (USA) ', 'PromoCell GmbH (Germany) ', 'Biological Industries Israel Beit Haemek Ltd. (Israel) ', 'Creative Bioarray (USA) ', 'Mycoplasma Experience (UK) ', 'Norgen Biotek Corp. (Canada) ', 'Biotools B & M Labs S.A. (Spain)'

    Demand for mycoplasma testing is increasing, driven by an upsurge in the research and development of biological products in biotechnology and pharmaceuticals, including cell-based medicines and vaccines. As more and more researchers increasingly rely on cell lines for manufacturing, the requirement for a mycoplasma infection-free cell line stream has become necessary. As businesses grow through giving increased priority to quality assurance during their research operations, mycoplasma testing market demand is rising along with the need for rigorous testing methodologies. 

    Integration of Automation in Testing: Automation in the operations of laboratories and testing operations such as mycoplasma testing is now quite a routine affair. Automated systems ensure reduction of testing time to a level that is significantly lower, productivity increases sharply, and human errors are considerably minimized. The expanding interest of biopharmaceutical companies in enhancing process efficiency with uniform quality will keep on boosting their demand for mycoplasma testing technology companies.

    According to the global mycoplasma testing market forecast, North America led the market in 2023 with a revenue share of 39.04%. A combination of several factors leads to a high mycoplasma testing market share. Prevalence of respiratory disorders is also at a high level and the rising investment in biotechnology by major companies since its wide application in cancer research and developing novel biologics, vaccines, and drugs. Besides, through the development and integration of strict regulatory requirements, companies such as the FDA and the U.S. Department of Health and Human Services, in collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, continually advance standards on the testing of biological and microbiological safety of biomedical laboratories. 

    Related Reports

    In-Vitro Diagnostics Market
    Buy Now GET FREE SAMPLE
    Immunodiagnostics Market
    Buy Now GET FREE SAMPLE
    Immunoprotein Diagnostic Testing Market
    Buy Now GET FREE SAMPLE
    Clinical Laboratory Tests Market
    Buy Now GET FREE SAMPLE
    Cancer Diagnostics Market
    Buy Now GET FREE SAMPLE
    Rapid Diagnostics Market
    Buy Now GET FREE SAMPLE
    Immunohematology Market
    Buy Now GET FREE SAMPLE
    Tissue Diagnostics Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Mycoplasma Testing Market

    Report ID: SQMIG35I2219

    $5,300
    BUY NOW